DE602005022471D1 - Zusammensetzungen enthaltend lipase, protease und amylase zur behandlung von pankreasinsuffizienz - Google Patents

Zusammensetzungen enthaltend lipase, protease und amylase zur behandlung von pankreasinsuffizienz

Info

Publication number
DE602005022471D1
DE602005022471D1 DE602005022471T DE602005022471T DE602005022471D1 DE 602005022471 D1 DE602005022471 D1 DE 602005022471D1 DE 602005022471 T DE602005022471 T DE 602005022471T DE 602005022471 T DE602005022471 T DE 602005022471T DE 602005022471 D1 DE602005022471 D1 DE 602005022471D1
Authority
DE
Germany
Prior art keywords
compositions
treatment
amylase
protease
lipase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005022471T
Other languages
English (en)
Inventor
Alexey L Margolin
Bhami C Shenoy
Frederick T Murray
Anthony Christopher Lee Stevens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cystic Fibrosis Foundation
Original Assignee
Altus Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altus Biologics Inc filed Critical Altus Biologics Inc
Publication of DE602005022471D1 publication Critical patent/DE602005022471D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
DE602005022471T 2004-10-14 2005-10-14 Zusammensetzungen enthaltend lipase, protease und amylase zur behandlung von pankreasinsuffizienz Active DE602005022471D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61876404P 2004-10-14 2004-10-14
PCT/US2005/036802 WO2006044529A1 (en) 2004-10-14 2005-10-14 Compositions containing lipase; protease and amylase for treating pancreatic insufficiency

Publications (1)

Publication Number Publication Date
DE602005022471D1 true DE602005022471D1 (de) 2010-09-02

Family

ID=35840531

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005022471T Active DE602005022471D1 (de) 2004-10-14 2005-10-14 Zusammensetzungen enthaltend lipase, protease und amylase zur behandlung von pankreasinsuffizienz

Country Status (24)

Country Link
US (1) US7718169B2 (de)
EP (2) EP2198880B1 (de)
JP (1) JP4908420B2 (de)
KR (1) KR101333664B1 (de)
CN (1) CN101068565B (de)
AT (1) ATE474592T1 (de)
AU (1) AU2005295754B2 (de)
BR (1) BRPI0516515B1 (de)
CA (1) CA2584069C (de)
CY (2) CY1110838T1 (de)
DE (1) DE602005022471D1 (de)
DK (2) DK2198880T3 (de)
ES (2) ES2614157T3 (de)
HK (1) HK1109068A1 (de)
HR (1) HRP20161684T1 (de)
HU (1) HUE031245T2 (de)
LT (1) LT2198880T (de)
MX (1) MX2007004534A (de)
PL (2) PL1809320T3 (de)
PT (2) PT1809320E (de)
RU (1) RU2385736C2 (de)
SI (2) SI2198880T1 (de)
UA (1) UA91521C2 (de)
WO (1) WO2006044529A1 (de)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20010046493A1 (en) * 2000-02-24 2001-11-29 Alex Margolin Lipase-containing composition and methods of use thereof
US20070053895A1 (en) * 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
PT1729797E (pt) 2004-03-22 2008-12-17 Solvay Pharm Gmbh Composições farmacêuticas orais de produtos contendo lipase, em particular de pancreatina, contendo tensioactivos
EP1771194A2 (de) * 2004-07-07 2007-04-11 Biodevelops Pharma Entwicklung GmbH Verwendung einer deubiquitinierenden verbindung zur steigerung der expression von membranproteinen auf der zelloberfläche
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
CA2616943C (en) 2005-07-29 2016-04-12 Solvay Pharmaceuticals Gmbh Processes for the manufacture of sterilized pancreatin powder
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US20070116695A1 (en) * 2005-09-21 2007-05-24 Fallon Joan M Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
US8071089B2 (en) 2005-11-01 2011-12-06 Bio-Cat, Inc. Composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrosis as well as people suffering from pancreatic lipase insufficiency
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
EP2455461B1 (de) 2006-12-21 2016-03-16 Novozymes A/S Lipasevarianten zur pharmazeutischen Verwendung
US20080199448A1 (en) * 2007-02-16 2008-08-21 Ross Mairi R Enzyme composition for improving food digestion
TWI609693B (zh) 2007-02-20 2018-01-01 艾泰醫藥有限公司 穩定之消化酵素組合物
RU2445952C2 (ru) * 2007-02-20 2012-03-27 Юранд Фармасьютикалз Лимитед Стабильные композиции пищеварительных ферментов
WO2009109856A2 (en) 2008-03-07 2009-09-11 Axcan Pharma Inc. Method for detecting infectious parvovirus in pharmaceutical preparations
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US20090324730A1 (en) * 2008-06-26 2009-12-31 Fallon Joan M Methods and compositions for the treatment of symptoms of complex regional pain syndrome
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US11016104B2 (en) 2008-07-01 2021-05-25 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) * 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
EP2328609A1 (de) * 2008-08-26 2011-06-08 Cystic Fibrosis Foundation Therapeutics, Inc. Schnell auflösende tabletten mit lipase, amylase und protease
EP2165717A1 (de) 2008-08-27 2010-03-24 Nordmark Arzneimittel GmbH & Co.KG Verfahren zur Verringerung der viralen und mikrobiellen Belastung feststoffhaltiger biologischer Extrakte
US20110171294A1 (en) * 2008-09-30 2011-07-14 Dsm Ip Assets B.V. Enzyme composition and application thereof in the treatment of pancreatic insufficiency
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
CN105031628B (zh) * 2009-01-06 2020-10-02 加尔纳根有限责任公司 治疗或预防大肠杆菌导致的经口感染的组合物和方法
ES2882518T3 (es) 2009-01-06 2021-12-02 Galenagen Llc Composición que comprende proteasa, amilasa y lipasa
AU2015252099B2 (en) * 2009-01-06 2017-08-10 Galenagen, Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
WO2010085975A1 (de) 2009-01-29 2010-08-05 Nordmark Arzneimittel Gmbh & Co. Kg Pharmazeutisches präparat enthaltend lipase bakteriellen ursprungs
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
WO2010130622A1 (en) * 2009-05-11 2010-11-18 Dsm Ip Assets B.V. Enzyme composition for the treatment of prancreatic insufficiency
EP2295039B2 (de) 2009-08-28 2022-10-26 Nordmark Pharma GmbH Verfahren zur Herstellung von Pankreatin-Pellets, insbesondere Pankreatin-Mikropellets, und hiernach hergestellte Pankreatin-Pellets
US8784884B2 (en) * 2009-09-17 2014-07-22 Stephen Perrett Pancreatic enzyme compositions and methods for treating pancreatitis and pancreatic insufficiency
AU2016216662B2 (en) * 2009-09-17 2017-09-07 Allergan Therapeutics LLC Pancreatic enzyme compositions and methods for treating pancreatitis and pancreatic insufficiency
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
EP2509635A4 (de) * 2009-12-08 2013-09-18 Depomed Inc Gastroretentive pharmazeutische zusammensetzungen zur verlängerten freisetzung von polypeptiden
JP2011162491A (ja) * 2010-02-10 2011-08-25 Ezaki Glico Co Ltd 乾燥麹抽出物及びこれを用いた口腔用組成物
SE535296C2 (sv) * 2010-09-08 2012-06-19 Anara Ab Mognad av mag-tarmkanalen
PT2621476E (pt) 2010-10-01 2014-10-16 Aptalis Pharma Ltd Formulações de pancrelipase de baixa potência com revestimento entérico
FR2966734B1 (fr) * 2010-10-29 2014-07-18 Max Rombi Composition comprenant au moins une enzyme proteolytique pour son utilisation pour empecher la synthese des triglycerides
PL2489349T3 (pl) 2011-02-17 2014-09-30 Nordmark Arzneimittel Gmbh & Co Kg Granulki pankreatynowe, zwłaszcza mikrogranulki pankreatynowe, oraz sposób ich produkcji
MX347770B (es) 2011-04-21 2017-05-12 Curemark Llc Compuesto para el tratamiento de alteraciones neuropsiquiatricas.
HUE026560T2 (hu) 2011-08-08 2016-06-28 Allergan Pharmaceuticals Int Ltd Eljárás emésztõ enzimeket tartalmazó szilárd készítmények feloldódási viselkedésének vizsgálatára
US8268305B1 (en) 2011-09-23 2012-09-18 Bio-Cat, Inc. Method and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase
DK3384902T3 (da) 2012-02-17 2021-01-18 Alcresta Therapeutics Inc Fremgangsmåder, sammensætninger og indretninger til opfyldelse af diætmæssige behov for fedtsyre
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
EP2897604B1 (de) * 2012-09-19 2018-07-04 Grespo AB Zusammensetzungen zur verbesserung der hirnfunktion
JP2016513634A (ja) 2013-03-15 2016-05-16 アプタリス ファーマ リミテッド 消化酵素および栄養素を含む経腸投与に適した組成物
WO2014172309A2 (en) 2013-04-18 2014-10-23 The United States Of America As Represented By The Secretary Of The Army, On Behalf Of The United Therapeutic compositions for neutralizing type i interferons, and methods of use
BR112016001289A2 (pt) 2013-07-22 2018-03-20 Allergan Pharmaceuticals International Limited pancreatina de alta atividade (ha-pancreatina), composição farmacêutica de alta potência, processo para preparação da ha-pancreatina com atividade de lipase específica de, pelo menos, cerca de 120 ui usp/mg e método de tratamento de um paciente que apresenta uma condição fisiológica associada à insuficiência enzimática pancreática
MX2016001593A (es) 2013-08-09 2016-09-29 Allergan Pharmaceuticals Int Ltd Composicion de enzima digestiva adecuada para administracion enterica.
KR20170052520A (ko) 2013-11-05 2017-05-12 앨러간 파마슈티컬스 인터내셔널 리미티드 고효능 판크레아틴 약학적 조성물
JP2014193909A (ja) * 2014-06-04 2014-10-09 Nordmark Arzneimittel Gmbh & Co Kg 医薬調製物
EP3157568A1 (de) 2014-06-19 2017-04-26 Aptalis Pharma Limited Verfahren zur entfernung von viralen verunreinigungen aus pankreatischen extrakten
GB201501081D0 (en) 2015-01-22 2015-03-11 Cilian Ag Use of enzymes with a wide pH activity range as medicaments for promoting digestion
JP6797107B2 (ja) * 2015-03-02 2020-12-09 東レ株式会社 膵臓機能異常の検出方法及び検出用キット
DE102015114859A1 (de) 2015-09-04 2017-03-09 Nordmark Arzneimittel Gmbh & Co. Kg Verwendung einer pharmazeutischen Zusammensetzung, enthaltend mindestens ein Verdauungsenzym, bei der künstlichen Ernährung
US10258590B2 (en) 2015-10-14 2019-04-16 Alcresta Therapeutics, Inc. Enteral feeding device and related methods of use
DE102017104472A1 (de) 2017-03-03 2018-09-06 Nordmark Arzneimittel Gmbh & Co. Kg Schmelztablette enthaltend Burlulipase und daraus hergestellte pharmazeutische Zusammensetzung
US11045396B2 (en) 2017-08-17 2021-06-29 Alcresta Therapeutics, Inc. Devices and methods for the supplementation of a nutritional formula
FR3079146B1 (fr) 2018-03-23 2020-04-17 Karim Ioualalen Formulation gastroprotectrice de complexes d’enzymes permettant de restaurer la fonction digestive.
US11547745B1 (en) * 2018-08-23 2023-01-10 Vets Plus, Inc. Compositions and methods for treating pancreatic enzyme deficiencies in mammals
MX2022002473A (es) 2019-08-30 2022-08-02 Codexis Inc Variantes de lipasa modificadas geneticamente.
US20230138700A1 (en) * 2020-03-30 2023-05-04 Jai WALL Combined animal-derived and synthetically produced pancreatic enzyme replacement therapy
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
CA3233449A1 (en) * 2021-09-30 2023-04-06 Robert Gallotto Engineered lipase enzymes, manufacture and use thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5017559B2 (de) 1972-09-20 1975-06-21
JPS5428820Y2 (de) * 1974-06-14 1979-09-14
GB1509866A (en) * 1975-06-10 1978-05-04 Johnson & Johnson Enteric coated digestive enzyme compositions
US4659667A (en) * 1985-02-26 1987-04-21 Miles Laboratories, Inc. Process to recover crystalline enzymes and crystalline enzymes produced thereby
DK154572C (da) * 1985-08-07 1989-04-24 Novo Industri As Enzymatisk detergentadditiv, detergent og fremgangsmaade til vask af tekstiler
JP3079276B2 (ja) * 1988-02-28 2000-08-21 天野製薬株式会社 組換え体ｄｎａ、それを含むシュードモナス属菌及びそれを用いたリパーゼの製造法
DE3808695A1 (de) * 1988-03-16 1989-10-05 Henkel Kgaa Fluessiges waschmittel
DK0387945T3 (da) 1989-03-08 1993-12-20 Simon Lodewijk Scharpe Middel til behandling af eksokrin pancresinsufficiens og midlets anvendelse til fremstilling af et lægemiddel til behandlingen
DE69003253T2 (de) 1989-12-21 1994-01-20 Novonordisk As Enzymhaltige zubereitung und eine solche zubereitung enthaltendes detergens.
DK173590D0 (da) 1990-06-06 1990-07-19 Novo Nordisk As Rekombinante terapeutiske lipaser
SK283185B6 (sk) 1990-08-03 2003-03-04 Vertex Pharmaceuticals Incorporated Zosietené kryštály proteínov, zariadenie ich obsahujúce a ich použitie
US5618710A (en) * 1990-08-03 1997-04-08 Vertex Pharmaceuticals, Inc. Crosslinked enzyme crystals
US5892013A (en) * 1990-09-13 1999-04-06 Novo Nordisk A/S Lipase variants
ATE175117T1 (de) * 1991-07-01 1999-01-15 Basf Ag Verwendung von lipasen zur herstellung von arzneimitteln
EP0681609A1 (de) * 1991-12-20 1995-11-15 Novo Nordisk A/S Verfahren zur herstellung von lipase
US5928640A (en) * 1992-06-30 1999-07-27 Cortecs Limited Use of enzymes, especially bromelain, in the treatment of diarrhoea
DK154292D0 (da) * 1992-12-23 1992-12-23 Novo Nordisk As Nyt enzym
DK39693D0 (da) * 1993-04-02 1993-04-02 Novo Nordisk As Enzym
GB9403344D0 (en) * 1994-02-22 1994-04-13 Cortecs Ltd Medical application of bromelain
DE4408152A1 (de) * 1994-03-11 1995-09-14 Studiengesellschaft Kohle Mbh Immobilisierte Lipasen in hydrophoben Sol-Gel-Materialien
DK0755442T3 (da) * 1994-05-04 2003-04-14 Genencor Int Lipaser med forbedret resistens over for overfladeaktive midler
ATE287725T1 (de) 1995-05-31 2005-02-15 Medzyme N V Zusammensetzungen zur verbesserung der verdaulichkeit und ausnutzung von nähestoffen
US5932212A (en) * 1996-05-24 1999-08-03 Altus Biologics, Inc. Crosslinked protein crystal formulations and their use as catalysts in organic solvents
US5750104A (en) * 1996-05-29 1998-05-12 Digestive Care Inc. High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith
US6140475A (en) 1997-04-11 2000-10-31 Altus Biologics Inc. Controlled dissolution crosslinked protein crystals
AU8772498A (en) 1997-09-05 1999-03-29 Altus Biologics Inc. Carbohydrate crosslinked glycoprotein crystals
US6013680A (en) * 1997-10-21 2000-01-11 Amano Pharmaceutical Co., Ltd. Digestive enzyme-containing medicament
US6541606B2 (en) * 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
US6156552A (en) * 1998-02-18 2000-12-05 Novo Nordisk A/S Lipase variants
EP2311436A1 (de) 1998-04-27 2011-04-20 Altus Pharmaceuticals Inc. Stabilisierte Protein-Kristalle, diese enthaltende Formulierungen und ihre Herstellungsverfahren
US6042823A (en) * 1998-07-02 2000-03-28 Amano Pharmaceuticals Co., Ltd. Enzyme composition and use thereof
US20010046493A1 (en) * 2000-02-24 2001-11-29 Alex Margolin Lipase-containing composition and methods of use thereof
AR032392A1 (es) * 2001-01-19 2003-11-05 Solvay Pharm Gmbh Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado.

Also Published As

Publication number Publication date
JP2008516965A (ja) 2008-05-22
JP4908420B2 (ja) 2012-04-04
KR20070074622A (ko) 2007-07-12
ATE474592T1 (de) 2010-08-15
CN101068565B (zh) 2010-11-17
RU2385736C2 (ru) 2010-04-10
CY1118597T1 (el) 2017-07-12
WO2006044529A1 (en) 2006-04-27
DK1809320T3 (da) 2010-11-15
KR101333664B1 (ko) 2013-11-28
US20060121017A1 (en) 2006-06-08
AU2005295754B2 (en) 2010-09-09
EP2198880A1 (de) 2010-06-23
EP2198880B1 (de) 2016-11-23
BRPI0516515B1 (pt) 2018-05-29
LT2198880T (lt) 2017-02-27
SI2198880T1 (sl) 2017-02-28
BRPI0516515A (pt) 2008-09-16
AU2005295754A1 (en) 2006-04-27
PT2198880T (pt) 2017-01-04
ES2352086T3 (es) 2011-02-15
CA2584069A1 (en) 2006-04-27
PT1809320E (pt) 2010-10-25
HK1109068A1 (en) 2008-05-30
AU2005295754A2 (en) 2010-09-02
DK2198880T3 (en) 2017-01-23
PL1809320T3 (pl) 2011-11-30
UA91521C2 (ru) 2010-08-10
HUE031245T2 (en) 2017-06-28
PL2198880T3 (pl) 2017-04-28
US7718169B2 (en) 2010-05-18
CY1110838T1 (el) 2015-06-10
CN101068565A (zh) 2007-11-07
CA2584069C (en) 2017-02-07
SI1809320T1 (sl) 2010-11-30
HRP20161684T1 (hr) 2017-02-24
MX2007004534A (es) 2007-11-08
EP1809320A1 (de) 2007-07-25
RU2007117728A (ru) 2008-11-20
EP1809320B1 (de) 2010-07-21
ES2614157T3 (es) 2017-05-29

Similar Documents

Publication Publication Date Title
DE602005022471D1 (de) Zusammensetzungen enthaltend lipase, protease und amylase zur behandlung von pankreasinsuffizienz
DE60330161D1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
ATE439863T1 (de) Ophthalmische zusammensetzungen von parasympathischen stimulantia und entzündungshemmer zur verwendung bei der behandlung von presbyopie
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
ATE526991T1 (de) Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
DE602005011656D1 (de) Verfahren zur behandlung von dickdarmkrebs mit botulinum neurotoxin
DK1615952T3 (da) Fremgangsmåder til behandling af betændelsestilstande med specifikke, til humant angiopoietin-2-bindende midler
ATE446754T1 (de) Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten
ATE460923T1 (de) Lyophilisierung von virosomen
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
ATE542535T1 (de) Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheiten
ATE519504T1 (de) Chromatin-remodellierende substanzen zur erhöhung der expression von pdx-1 und förderung der zelldifferenzierung
DE602006009786D1 (de) Anwendung von molekülen und verfahren zur behandlung von mit mcp-1/ccr2 assoziierten krankheiten
DE60335647D1 (de) Pyrroloquinoline quinone und ein betablocker zur behandlung von ischämie oder reperfusionsschäden
ATE473277T1 (de) Zusammensetzungen und verfahren zur prävention und behandlung von immunvermittelten entzündungskrankheiten
DE602005013650D1 (de) Proteinhydrolysat zur behandlung von müdigkeit
DE602004028574D1 (de) Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie
DE60313803D1 (de) Cathepsincysteinproteaseinhibitoren und deren verwendung zur behandlung von entzündungen und immunerkrankungen
DE602005015434D1 (de) Mittel zur behandlung von psychoneurotischen krankheiten
DE602005016697D1 (de) Molekulardiagnoseverfahren und behandlung von demenz mit lewy-körperchen
EA200601392A1 (ru) Способы и композиции для лечения липодистрофии
ATE427754T1 (de) Verwendung von il-17f zur behandlung und/oder pravention von neurologischen erkrankungen
DE602005018941D1 (de) Verwendung von winterbohnenkraut (satureja montana) oder seinen extrakten zur herstellung von medikamenten zur behandlung von vorzeitiger ejakulation
DE60320422D1 (de) Verfahren und formulierungen, die sich für die reduktion des cholesteringehalts von eigelb eignen
DE112006002215A5 (de) Proteinzusammensetzung zur Behandlung von Proteinmangelzuständen

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC., , US